AUSTIN, Texas & AMSTERDAM, The Netherlands--(BUSINESS WIRE)--Asuragen, Inc., an oncology molecular diagnostic company and molecular biology service provider, today announced it has granted a non-exclusive license to Agendia, B.V., a gene expression analysis-based diagnostics and clinical testing company. Under the terms of this agreement, Agendia has the right to use RNARetain globally for human diagnostic applications.
